Medicxi Closes €500M Fund V to Accelerate Asset-Centric Biotech Investments
核心洞察
Medicxi (搜索) successfully raised €500 million ($581 million) for its sixth fund, demonstrating strong investor confidence in its asset-centric investment approach.
The fund will support biotechnology companies at all stages of drug development, focusing on single-asset companies with clear product visions to transform patient care.
Since its previous fund, Medicxi (搜索) has created 16 new companies, achieved over 20 positive clinical data readouts, and realized more than $1 billion in returns across its portfolio.
Anglo-Swiss life sciences investment company Medicxi (搜索) has successfully closed its sixth fund, raising €500 million (approximately $581 million) to continue building and backing biotechnology companies focused on transforming patient care. The oversubscribed fund demonstrates strong investor confidence in Medicxi's asset-centric investment approach and attracted support from existing limited partners alongside a selected group of new institutional investors.
The new Medicxi (搜索) V fund will concentrate on "building and backing innovative biotechnology companies with clear product visions to transform patient care," according to the firm. The fund maintains Medicxi's dual investment strategy of creating companies from the ground up and investing in existing biotechnology companies at various development stages that align with the firm's asset-centric value creation methodology.
Investment Strategy and Capital Efficiency
"We are focused on backing scientific entrepreneurs with a clear product vision and, as a result, drive all financial and intellectual resources on a single asset in development," Giovanni Mariggi, partner at Medicxi (搜索), explained. "We do not dilute attention or capital on platform development or labs costs, so 100% of the decision making is fixed on go/no-go decisions centered on the asset itself."
This approach enables Medicxi (搜索) to operate an investment model that is "extremely capital efficient and nimble in an industry which is renowned for inefficient capital deployment and moving slowly." The firm minimizes fixed costs by using outsourced CROs and operating lean personnel teams while trenching capital deployment based on clear value inflection points.
Portfolio Performance and Notable Successes
The fundraising success comes following strong portfolio performance since Medicxi (搜索)'s previous funding round. The firm has created 16 new companies, delivered more than 20 positive clinical data readouts, and realized over $1 billion in returns across its portfolio.
Highlights from the portfolio include investments in US biotech Vaxcyte, which is currently preparing late-stage trials of new pneumococcal vaccine candidates for adults and children that promise to provide broader protection than rival shots from Pfizer and MSD. The portfolio also features France's Abivax, which has positive phase 3 results for obefazimod (ABX464) in ulcerative colitis (搜索).
Three biotechs in the portfolio have been acquired by larger companies, generating significant returns. Cancer (搜索) immunotherapy developer Merus and antibody-drug conjugate (ADC) specialist ProfoundBio (搜索) were purchased for $8 billion and $1.8 billion, respectively, by Genmab. Meanwhile, Sanofi acquired UK vaccines developer ViceBio (搜索) for $1.6 billion. Additionally, Eli Lilly acquired Versanis Bio from the portfolio.
Decade of Growth and Market Position
The latest fund brings Medicxi (搜索)'s total capital commitments to over €2 billion ($2.3 billion) across six funds over the past decade. The oversubscribed raise comes two years after Medicxi raised €400 million for its Medicxi IV fund.
"The Medicxi (搜索) team has been operating for over 20 years (formerly the Index Ventures life sciences team). As a result, it has established a unique and differentiated platform which attracts cutting-edge science and highly innovative, seasoned drug development teams," Mariggi noted.
The firm's approach includes self-funding its own companies in the earliest phases, relying on external financing only once specific drug development inflection points have been met. This strategy allows Medicxi (搜索) to retain significant ownership in its companies (50%+) and reduces reliance on outsized exit valuations to drive material returns.
Leadership and Future Focus
Medicxi (搜索) also announced that Shyam Masrani, who led the firm's investments in Merus and ProfoundBio (搜索) and currently serves on the boards of Acera Therapeutics, T-CypherBio and Petalion Therapeutics, has been promoted to partner.
"Medicxi (搜索)'s longstanding success has been founded on its unique ties to leading global pharmaceutical companies and its world-class team of drug hunters and clinicians," said Francesco De Rubertis, co-founder and partner at Medicxi. "The new €500 million fund will enable Medicxi to provide the critical capital, expertise, and experience to deliver transformative therapies for patients."
The firm has recently participated in sizeable funding rounds for cancer (搜索)-focused biotechs Ottimo Pharma (搜索) and FORE Biotherapeutics (搜索), as well as varicella zoster virus (搜索) (VZV) developer Curevo (搜索), indicating continued active investment in innovative therapeutic areas.